Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四 環 醫 藥 控 股 集 團 有 限 公 司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026

At the annual general meeting (the "**AGM**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**") held on 26 June 2026, all the proposed resolutions as set out in the notice of the AGM dated 3 June 2026 were taken by way of poll.

As at the date of the AGM, the total number of issued shares of the Company was 9,329,999,206 shares. The trustee (the "**Trustee**") of share award scheme adopted by the Company on 25 October 2022 (the "**2022 Share Award Scheme**"), held 130,188,000 shares as at the date of the AGM, which was required under Rule 17.05A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") to abstain from voting on matters that require the approval of the Company's shareholders ("**Shareholder(s)**") under the Listing Rules and on all the proposed resolutions pursuant to the rules of the 2022 Share Award Scheme. As at the date of the AGM, (i) the Company held and completed delivery of 204,011,000 treasury shares (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited), and (ii) no shares repurchased by the Company which are pending cancellation. The Company confirmed that no voting rights of treasury shares have been exercised at the AGM. Save for the aforesaid, there were no shares entitling the holder to attend and abstain from voting in favour of the proposed resolutions at the AGM under Rule 13.40 of the Listing Rules. No party has stated its intention in the circular of the Company dated 3 June 2026 that it would vote against any proposed resolution or that it would abstain from voting at the AGM. As such, there were a total of 8,995,800,206 shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM.

The Hong Kong branch share registrar of the Company, Tricor Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. All the resolutions were approved by the Shareholders. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS			**No. of Votes (%)**	
			For	**Against**
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors of the Company (the "**Directors**") and auditor of the Company (the "**Auditor**") for the year ended 31 December 2025.		5,580,172,432 (99.99)	477,970 (0.01)
2.	To approve the declaration and payment of a final cash dividend for the year ended 31 December 2025.		5,580,451,402 (99.99)	42,000 (0.01)
3.	(a)	To re-elect the following retiring Directors:		
		(i) Dr. Guo Weicheng as an executive Director	5,562,286,903 (99.67)	18,206,499 (0.33)
		(ii) Ms. Chen Yanling as an executive Director	5,521,119,260 (98.93)	59,519,142 (1.07)
		(iii) Dr. Zhu Xun as an independent non-executive Director	5,423,625,890 (97.19)	156,867,512 (2.81)
	(b)	To authorize the board of Directors (the "**Board**") to fix the remuneration of the Directors.	5,578,839,402 (99.97)	1,654,000 (0.03)
4.	To re-appoint the Auditor.		5,580,451,402 (99.99)	42,000 (0.01)
5.	(A)	To give a general mandate to the Directors to allot, issue and deal with the additional shares and/or to sell or transfer the treasury shares, the amount of which shall not exceed 20 per cent of the number of issued shares of the Company (excluding treasury shares, if any).	5,318,667,183 (95.29)	262,834,219 (4.71)
	(B)	To give a general mandate to the Directors to repurchase shares not exceeding 10 per cent of the number of issued shares of the Company (excluding treasury shares, if any).	5,580,451,402 (99.99)	42,000 (0.01)
	(C)	To extend the authority given to the Directors pursuant to ordinary resolution no. 5(A) to issue shares, and/or to sell or transfer the treasury shares, by adding to the number of issued shares of the Company the number of shares repurchased under ordinary resolution no. 5(B).	5,318,667,183 (95.31)	261,826,219 (4.69)

ORDINARY RESOLUTIONS			No. of Votes (%)	
			For	Against
6.	(A)	To approve to terminate the existing share option scheme adopted by the shareholders of the Company at the general meeting held on 24 October 2017 and adopt the 2026 share incentive scheme (the "**2026 Share Incentive Scheme**") with the Scheme Mandate Limit (as defined in the 2026 Share Incentive Scheme) of 10% of the total issued and outstanding shares (excluding any treasury shares) as at the date of passing this resolution, and to authorize the Scheme Administrator (as defined in the 2026 Share Incentive Scheme) to grant the awards pursuant to the 2026 Share Incentive Scheme and do all such acts and execute all such documents as the Scheme Administrator may consider necessary or expedient in order to give full effect to the 2026 Share Incentive Scheme.	5,359,948,418 (96.05)	220,544,984 (3.95)
	(B)	To approve and adopt the Service Provider Sublimit (as defined in the 2026 Share Incentive Scheme) of 2% of the total issued and outstanding shares (excluding any treasury shares) as at the date of passing this resolution.	5,365,017,505 (96.14)	215,475,897 (3.86)

As more than 50% of votes were cast in favour of the resolutions numbered 1 to 6, all the above resolutions were duly passed as ordinary resolutions.

All Directors attended the AGM.

FURTHER INFORMATION ON THE PAYMENT OF THE FINAL CASH DIVIDEND

The proposed final cash dividend of RMB0.96 cents per share for the year ended 31 December 2025 has been approved by the Shareholders at the AGM. The final cash dividend payable to Shareholders shall be converted to and paid in HK$. The exchange rate adopted for conversion was based on the exchange rate of RMB1 to HK$1.133 as of 31 March 2026 (being the medium exchange rate of RMB to HK$ as announced by the People's Bank of China on the date of the Board meeting). Accordingly, the amount of the final cash dividend payable in HK$ will be HK1.09 cents per share. The final cash dividend will be payable on Thursday, 16 July 2026 to Shareholders whose names appear on the register of members of the Company on Monday, 6 July 2026.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

China, 26 June 2026

As at the date of this announcement, the executive Directors are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive Directors are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.